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Assessment of Treatment 
Response of Keloid Patients
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(*) indicates primary project advisor
(**) indicates another student who is declaring the same project as primary for SI
• Keloids =potentially genetically-driven benign tumor-like 
scars that grow beyond wound borders that appear to 
preferentially affect African Americans
• Why patients care à Range from asymptomatic, small 
papules to large, painful, itchy, raised plaques that are 
aesthetically unpleasing to patients
• Why we should care à Despite the great effect that these 
lesions can have on a patient’s quality of life, there is still a 
very limited amount of research literature on how to treat 
them most effectively




• No single treatment modality has proven effective, so we 
need adjuvant therapies
• OBJECTIVE: determine what currently available treatment 
works best for keloid patients in reducing the size and 
symptoms of their keloids
– Hope to build upon this information in the future as we explore new 
treatment options
Prophylaxis








Injection of triamcinolone + PRP intraoperatively
Brachytherapy during excision
Excision + PRP + post-op superficial radiation
Triamcinolone injections + PRP application or 5-
FU injection
Laser-assisted delivery of injected or topical 
steroids
• Research Question
– How do patient keloid outcomes post-ILK 
injections compare with outcomes post-surgical 
excision?
• Hypothesis





• Study design: Retrospective chart review with phone 
surveys
– Retrospective study revealed the need for prospective 
phone surveys due to lack of detailed information in and 
inconsistencies between encounter notes
• Population/study sample: 504 keloid patients treated 
at Jefferson in the past 2 years
• Comparison group: Patients receiving ILK vs. patients 
undergoing surgical excision
• Outcome measures: % change in lesion size, change 
in symptoms (pruritis, pain; on a scale of 0-10)
• Data source and collection: phone surveys based on 
preliminary data collection from retrospective chart 




– Pie charts, bar graphs
– 2-tailed t-test with equal variance
• Findings
– 84 patients with 114 keloids responded
– 16 keloids were excised and 90 were treated with Kenalog
– Size change findings
• Excision and Kenalog comparably produced some decrease in size
• More excised keloids resolved completely vs. more Kenalog-treated keloids decreased less 
than 50% in size
• Excision group showed more cases of increased keloid size
– Symptom score findings
• No significant difference in pruritus scores 
• Excisions reduced pain scores significantly
• No significant differences in either symptom score within keloid location groupings


While excised keloids and Kenalog-injected keloids comparably produced some 
decrease in size (81% vs. 78%), more excised keloids resolved completely (37% 
vs. 10%) and more Kenalog-treated keloids decreased less than 50% in size (41% 
vs. 19%). However, the excision group also showed more cases of increased keloid 
size (13% vs. 4%).
Comparison of symptom scores showed no significant difference in pruritus 
scores (p = 0.159), but demonstrated that excisions reduced pain scores 
significantly (p = 0.010).
Symptom Scores by Location
Symptom Scores by Location
Conclusions
• The results of this study suggest that excised keloids 
produce better size and pain reduction than Kenalog-
injected keloids
• These findings are the opposite of what was expected 
based on clinical experience and current literature
– Literature suggests that 50-80% of excised keloids recur
• BUT, outcome analysis was limited by the survey 
responses collected, as consenting patients mainly 
received Kenalog treatments (90 vs. 16)
• Further research is necessary to accurately determine 
which treatment modality is most effective before 
using this data to affect clinical practice
Future Directions
• Enroll more patients through in-person 
surveys in the keloid clinic (especially excision 
patients to allow for a better comparison)
• Clinical trials of new therapies, perhaps 
starting with more common and bothersome 
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